A Randomized, Controlled Phase 3 Study Of Pacritinib Versus Physician’s Choice In Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/Ìl)(PACIFICA) Read more
Individual Patient Supply Of Oral Pacritinib In A Patient With Thrombocytopenia And Primary Myelofibrosis. Read more
A Phase 1, First-In-Human, Dose Escalation Study Of JNJ-67571244 (Bispecific Antibody Targeting CD33 And CD3) In Subjects With Relapsed Or Refractory Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS) Read more
V-FAST: A Phase 1b Master Trial To Investigate CPX-351 Combined With Various Targeted Agents In Subjects With Previously Untreated Acute Myeloid Leukemia Read more
An Open-Label, Randomized Phase 3 Study Of MK-6482 Versus Everolimus In Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 And VEGF-Targeted Therapies Read more
A Phase 2, Randomized, Open-Label Three-Arm Clinical Study To Evaluate The Safety And Efficacy Of Lenvatinib (E7080/MK-7902) In Combination With Pembrolizumab (MK-3475) Versus Standard Of Care Chemotherapy And Lenvatinib Monotherapy In Participants With Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy And Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009) Read more
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Of Infigratinib For The Adjuvant Treatment Of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302) Read more
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Clinical Study Of Pembrolizumab (MK-3475) With Or Without Lenvatinib (E7080/MK-7902) To Evaluate The Safety And Efficacy Of Pembrolizumab And Lenvatinib As 1L Intervention In A PD-L1 Selected Population Of Participants With Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) Read more
A Study Of Enfortumab Vedotin (ASG-22CE) As Monotherapy Or In Combination With Other Anticancer Therapies For The Treatment Of Urothelial Cancer Read more
